Identification_NN
of_IN
sequence_NN
alterations_NNS
in_IN
the_DT
upstream_JJ
regulatory_JJ
region_NN
of_IN
the_DT
estrogen_NN
receptor_NN
gene_NN
in_IN
an_DT
ER-negative_JJ
breast_NN
cancer_NN
cell_NN
line_NN
._.

Given_IN
the_DT
important_JJ
role_NN
of_IN
the_DT
estrogen_NN
receptor_NN
-LRB-_-LRB-
ER_NN
-RRB-_-RRB-
in_IN
the_DT
development_NN
and_CC
physiology_NN
of_IN
the_DT
breast_NN
,_,
it_PRP
is_VBZ
essential_JJ
to_TO
delineate_VB
the_DT
mechanisms_NNS
responsible_JJ
for_IN
its_PRP$
failed_JJ
expression_NN
in_IN
some_DT
breast_NN
tumors_NNS
._.

We_PRP
have_VBP
cloned_VBN
and_CC
sequenced_VBN
a_DT
portion_NN
of_IN
the_DT
ER_NN
upstream_JJ
regulatory_JJ
region_NN
from_IN
the_DT
ER-positive_JJ
MCF-7_NN
and_CC
the_DT
ER-negative_JJ
MDA-MB-231_NN
breast_NN
cancer_NN
cell_NN
lines_NNS
to_TO
determine_VB
if_IN
sequence_NN
alterations_NNS
in_IN
this_DT
region_NN
account_VBP
for_IN
the_DT
ER-negative_JJ
phenotype_NN
of_IN
some_DT
tumors_NNS
._.

From_IN
this_DT
,_,
we_PRP
identified_VBD
a_DT
number_NN
of_IN
variations_NNS
between_IN
the_DT
sequences_NNS
,_,
two_CD
of_IN
which_WDT
were_VBD
determined_VBN
to_TO
be_VB
associated_VBN
with_IN
a_DT
50_CD
%_NN
decrease_NN
in_IN
CAT_NN
activity_NN
._.

